Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, 02881, USA.
Department of Neurology, Stanford University, Palo Alto, CA, USA.
Drug Saf. 2023 Mar;46(3):257-271. doi: 10.1007/s40264-022-01267-z. Epub 2023 Jan 16.
Receipt of opioid agonist treatment during early and late pregnancy for opioid use disorder may relate to varying perinatal risks. We aimed to assess the effect of time-varying prenatal exposure to opioid agonist treatment using buprenorphine or methadone on adverse neonatal and pregnancy outcomes.
We conducted a retrospective cohort study of pregnant women with opioid use disorder using Rhode Island Medicaid claims data and vital statistics during 2008-16. Time-varying exposure was evaluated in early (0-20 weeks) and late (≥ 21 weeks) pregnancy. Marginal structural models with inverse probability of treatment weighting were applied.
Of 400 eligible pregnancies, 85 and 137 individuals received buprenorphine and methadone, respectively, during early pregnancy. Compared with 152 untreated pregnancies with opioid use disorders, methadone exposure in both periods was associated with an increased risk of preterm birth (adjusted odds ratio [aOR]: 2.52; 95% confidence interval [CI] 1.07-5.95), low birth weight (aOR: 2.99; 95% CI 1.34-6.66), neonatal intensive care unit admission (aOR, 5.04; 95% CI 2.49-10.21), neonatal abstinence syndrome (aOR: 11.36; 95% CI 5.65-22.82), respiratory symptoms (aOR, 2.71; 95% CI 1.17-6.24), and maternal hospital stay > 7 days (aOR, 14.51; 95% CI 7.23-29.12). Similar patterns emerged for buprenorphine regarding neonatal abstinence syndrome (aOR: 10.27; 95% CI 4.91-21.47) and extended maternal hospital stay (aOR: 3.84; 95% CI 1.83-8.07). However, differences were found favoring the use of buprenorphine for preterm birth versus untreated pregnancies (aOR: 0.17; 95% CI 0.04-0.77), and for several outcomes versus methadone.
Methadone and buprenorphine prescribed for the treatment of opioid use disorder during pregnancy are associated with varying perinatal risks. However, buprenorphine may be preferred in the setting of pregnancy opioid agonist treatment. Further research is necessary to confirm our findings and minimize residual confounding.
在妊娠早期和晚期接受阿片类激动剂治疗(治疗阿片类使用障碍)可能与不同的围产期风险有关。我们旨在评估使用丁丙诺啡或美沙酮进行的产前时间变化(0-20 周和≥21 周)的阿片类激动剂治疗对不良新生儿和妊娠结局的影响。
我们使用罗德岛州医疗补助索赔数据和 2008-16 年期间的生命统计数据,对患有阿片类使用障碍的孕妇进行了回顾性队列研究。早期(0-20 周)和晚期(≥21 周)妊娠时评估了时间变化的暴露情况。采用逆概率治疗加权的边缘结构模型进行分析。
在 400 例合格妊娠中,85 例和 137 例分别在妊娠早期接受了丁丙诺啡和美沙酮治疗。与未经治疗的 152 例患有阿片类使用障碍的妊娠相比,在两个时期接受美沙酮治疗与早产(调整后的优势比[aOR]:2.52;95%置信区间[CI] 1.07-5.95)、低出生体重(aOR:2.99;95%CI 1.34-6.66)、新生儿重症监护病房入院(aOR,5.04;95%CI 2.49-10.21)、新生儿戒断综合征(aOR:11.36;95%CI 5.65-22.82)、呼吸症状(aOR,2.71;95%CI 1.17-6.24)和母亲住院时间>7 天(aOR,14.51;95%CI 7.23-29.12)的风险增加有关。丁丙诺啡在新生儿戒断综合征(aOR:10.27;95%CI 4.91-21.47)和产妇住院时间延长(aOR:3.84;95%CI 1.83-8.07)方面也出现了类似的模式。然而,与未接受治疗的妊娠相比,丁丙诺啡治疗早产的优势比(aOR:0.17;95%CI 0.04-0.77)和丁丙诺啡治疗的几项结果与美沙酮相比,丁丙诺啡治疗具有优势。需要进一步的研究来证实我们的发现并尽量减少残余混杂。